MULTIVA® Motion

Natural Analgesic and Anti-inflammatory Formulated in Highly Palatable Chews for Dogs with Moderate Articular Wear

Active ingredients (per chew): Methyl-Sulphonyl-Methane (MSM)

500 mg

Composition (in descending order): Brewer's yeast, methyl-sulphonyl-methane, glycerine, whey, duck aroma, rapeseed oil, soya lecithin, maltodextrin, calcium sulphate.

Analytical constituents: Crude protein 18.30%; crude oils and fats 9.31%; crude fibre 0.76%; crude ash 4.07%. moisture 5.25%.

Properties and mechanism of action:

- Methylsulphonylmethane (MSM) is a natural organic compound rich in sulphur (34% elemental sulphur). It is found naturally in many foods (certain fruits, vegetables, grains and meat) and even in human beings. It is a white crystalline substance which is odourless and has a slightly bitter taste. MSM is an oxidative metabolite of dimethylsulphoxide (DMSO).
- MSM provides sulphur which is used in the body to hold together the protein chains of connective tissue, hair and nails. Also for forming cysteine, an essential amino acid in the production of collagen, the natural repairer of the connective tissue in joints and ligaments.
- It has been discovered that the joints of horses with arthritis have lower levels of sulphur, approximately 1/3, than normal joints (Rizzo et col, 1995).
- In vitro studies indicate that MSM has anti-inflammatory and antioxidant properties (Alam SS et col, 1983; Beilke MA et col, 1987).
- In a double-blind study in people with osteoarthritis of the knee the administration of MSM resulted in a significant decrease in pain, clinical improvement and the ability to perform activities in daily life when compared to the placebo (Kim et al , 2006).
- Other studies in people and animals have proven that MSM reduces pain and inflammation, increases joint flexibility and reduces recovery time (Marañón et col, 2008; Usha et Naidu, 2004; Lawrence RM, 1998).
- The anti-inflammatory mechanism of action in MSM is independent of the Cyclooxygenase-2 inhibitors (COX-2. Ebisuzaki K., 2003).

Indications: To reduce pain and inflammation, and improve mobility and quality of life in dogs with moderate joint wear due to age, injury or intense exercise.

It is recommended to administer MULTIVA[®] Motion pre-emptively for older dogs (on reaching the equivalent of 50 human years old: 7 years in large breeds; 7.5 in medium breeds; and 8.5 in small breeds) in order to improve the pet's joint comfort, mobility and quality of life.

In dogs subjected to intense exercise (sport, work, etc.) MULTIVA® Motion, administered regularly,

helps prevent injuries by maintaining the structure and function of joints and the connective tissue thereof. Also indicated as a support in any chronic inflammatory process in dogs with a history of gastrointestinal, hepatic or renal problems, or older dogs.

Target species: Dogs.

Safety: A study in people which was 30 days long, using a dose of 2600 mg/day, did not reveal any side effects (Barrager et col, 2002).





Data Sheet



Features

Natural and gentle analgesic and anti-inflammatory action.

First choice for preventive use in older dogs (>7 years old), sport and working dogs...

Improves mobility and quality of life.

Ideal for prolonged use due to its lack of side effects.

Allows the use of anti-inflammatories to be reduced/eliminated.

Safe - without the side effects of NSAIDs.

Highly palatable chews - Facilitate daily intake.

Suitable for all ages and breeds.

Economical - Low cost/day.

MULTIVA® Motion

Natural Analgesic and Anti-inflammatory Formulated in Highly Palatable Chews for Dogs with Moderate Articular Wear

Studies in rats (Horváth et col, 2002) concluded that MSM is well tolerated both in acute overdose (2 g/kg in a single dose) as well as in chronic overdose (1.5 g/kg for 90 days).

Dosage: 1 chew per 15 kg body weight, once a day or divided into two separate doses (morning and evening).

Warnings: VetNova is a pioneer in the development of Chews technology to facilitate administration of supplements to cats and dogs. Unlike tablets, capsules, etc. which are administered in a "forced" manner to the mouth to ensure the product is taken, Chews should be administered freely in the pet's bowl and the pet left to take them voluntarily. Some shy cats and dogs may need a longer time to fully accept them, but once they do the daily intake is easier and more satisfactory. The following strategies can be used during the first week to facilitate initial acceptance: 1) Reduce the dose and gradually increase it, 2) Divide the daily dose into two separate doses (morning and evening), 3) Crush the chew and mix it with malt (cats), pate or any food which the pet enjoys, etc.

Keep the container tightly closed in a cool, dry place away from direct sunlight and out of reach of children and animals.

Presentation: 60 chews.

Supporting materials:

- Owner's brochure.
- Shelf display holder for owner's brochure.
- · Compilation of abstracts from published research articles.
- Selling tips (Spanish).

Bibliography:

- Alam SS, Layman DL. Dimethyl sulfoxide inhibition of prostacyclin production in cultured aortic endothelial cells, In: Anonymous. 411 ed. 1983;318-320.
- Alam SS, Layman DL. Dimethyl sulfoxide as a cholesterol-lowering agent in cultured fibroblasts exposed to low density lipoproteins in culture, Biochim Biophys Acta 1982;710:306-313.
- Anonymous. Methylsulfonylmethane Monograph, Alternative Medicine Review, 2003; Volume 8, Number 4, 438:441
 Barrager E, Veltmann JR Jr, Schauss AG, Schiller RN. A multicentered, open-label trial on the safety and efficacy of
- methylsulfonylmethane in the treatment of seasonal allergic rhinitis, J Altern Complement Med. 2002;8:167-173.
 Beilke MA, Collins-Lech C, Sohnle PG. Effects of dimethyl sulfoxide on the oxidative function of human neutrophils. In: Anonymous. 110 ed. 1987;91-96.
- Brien S et al. Systematic review of the nutritional supplements dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of osteoarthritis, Osteoarthritis Cartilage. 2008 Nov;16(11):1277-88.
- Calder PC et al. Inflammatory disease processes and interactions with nutrition, Br J Nutr. 2009 May;101 Suppl 1:S1-45.
- Cecil KM, Lin A, Ross BD, Egelhoff JC. Methylsulfonylmethane observed by in vivo proton magnetic resonance spectroscopy in a 5-year-old child with developmental disorder: effects of dietary supplementation, J Comput Assist Tomogr 2002;26:818-820.
- Childs SJ. Dimethyl sulfone (DMSO2) in the treatment of interstitial cystitis, Urol Clin North Am 1994;21:85-88.
- Cox WI, Specter S, Friedman H. Susceptibility of Friend erythroleukemia cells to natural cytotoxicity after in vitro treatment with dimethyl sulfoxide, Proc Soc Exp Biol Med 1982;169:337-342.
- Ebisuzaki K. Aspirin and methylsulfonylmethane (MSM): a search for common mechanisms, with implications for cancer prevention, Anticancer Res. 2003 Jan-Feb;23(1A):453-8.
- Horváth K et al. Toxicity of methylsulfonylmethane in rats, Food Chem Toxicol. 2002 Oct;40(10):1459-62.
- Jacob S and Appleton J. MSM: The Definitive Guide. A comprehensive review of the science and therapeutics of methylsulfonylmethane. Topanga: Freedom Press, 2003.







Data Sheet



MULTIVA® Motion

Natural Analgesic and Anti-inflammatory Formulated in Highly Palatable Chews for Dogs with Moderate Articular Wear

- Kim LS et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot study, OsteoArthritis and Cartilage. 2006; 14: 286-294.
- Lin A, Nguy CH, Shic F, Ross BD. Accumulation of methylsulfonylmethane in the human brain: identification by multinuclear magnetic resonance spectroscopy, Toxicol Lett 2001;123:169-177.
- Lawrence RM. Methylsulfonylmethane (MSM): a double-blind study of its use in degenerative arthritis. In: Anonymous. 1 ed. 1998;50.
- Layman DL. Growth inhibitory effects of dimethyl sulfoxide and dimethyl sulfone on vascular smooth muscle and endothelial cells in vitro, In Vitro Cell Dev Biol 1987;23:422-428.
- Layman DL, Jacob SW. The absorption, metabolism and excretion of dimethyl sulfoxide by rhesus monkeys, Life Sci 1985;37:2431-2437.
- Lyinan GH, Priesler HD. Membrane action of DMSO and other chemical enducers of Friend leukaemic cell differentiation, Nature 1976;262:361-363.
- Magnuson BA et al. Pharmacokinetics and distribution of [35S] methylsulfonylmethane following oral administration to rats, J Agric Food Chem. 2007 Feb 7;55(3):1033-8
- Marañón G et al. The effect of methyl sulphonyl methane supplementation on biomarkers of oxidative stress in sport horses following jumping exercise, Acta Vet Scand. 2008 Nov 7;50:45
- McCabe D, O'Dwyer P, Sickle-Santanello B, et al. Polar solvents in the chemoprevention of dimethylben-zanthracene-induced rat mammary cancer, Arch Surg 1986;121:1455-1459.
- Morton JI, Siegel BV. Effects of oral dimethyl sulfoxide and dimethyl sulfone on murine autoimmune lymphoproliferative disease, Proc Soc Exp Biol Med 1986:183:227-230.
- O'Dwyer PJ, McCabe DP, Sickle-Santanello BJ, et al. Use of polar solvents in chemoprevention of 1,2- dimethylhydrazineinduced colon cancer, Cancer 1988;62:944- 948.
- Parcell S. Sulfur in human nutrition and applications in medicine, Altern Med Rev. 2002 Feb;7(1):22-44.
- Pearson TW, Dawson HJ, Lackey HB. Natural occurring levels of dimethyl sulfoxide in selected fruits, vegetables, grains, and beverages, J Agric Food Chem 1981;29:1089-1091.
- Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis, J Urol 1988;140:36-39.
- Rizzo R, Grandolfo M, Godeas C, et al. Calcium, sulfur, and zinc distribution in normal and arthritic articular equine cartilage: a synchrotron radiation-induced X-ray emission (SRIXE) study. In: Anonymous. 273 ed. 1995;82-86.
- Rose SE, Chalk JB, Galloway GJ, Doddrell DM. Detection of dimethyl sulfone in the human brain by in vivo proton magnetic resonance spectroscopy, Magn Reson Imaging 2000;18:95-98.
- Tapiero H, Fourcade A, Billard C. Membrane dynamics of Friend leukaemic cells. II. Changes associated with cell differentiation, Cell Differ 1980;9:211-218.
- Usha P and Naidu M. Randomized, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis, Clin. Drug Invest. 2004;24(6): 363.

If you are interested in any of the articles listed, please do not hesitate to request them through the following contacts: vetnova@vetnova.net, +34 918 440 273, or your VetNova or Distributor Sales Representative.





Data Sheet



VetNova Teléf.: +34 918 440 273 · vetnova@vetnova.net · www.vetnova.net

